CRMP4 (Collapsin Response Mediator Protein 4), also known as DPYSL3 or DRP-3. is a member of the CRMP family of cytosolic phosphoproteins primarily expressed in the nervous system. These proteins play critical roles in neuronal development, including axon guidance, neurite outgrowth, and synaptic plasticity, by mediating signaling pathways such as Semaphorin 3A-induced growth cone collapse. CRMP4 is particularly associated with regulating microtubule dynamics and cytoskeletal reorganization during neurodevelopment.
CRMP4-specific antibodies are essential tools for studying its expression, localization, and interactions in both physiological and pathological contexts. Researchers use these antibodies in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate CRMP4's involvement in neurological disorders. Altered CRMP4 expression or post-translational modifications (e.g., phosphorylation) have been linked to neurodegenerative diseases (e.g., Alzheimer’s), neuropsychiatric conditions, and neural injury responses. For instance, CRMP4 upregulation is observed in reactive astrocytes following CNS damage, suggesting a role in glial scar formation. Additionally, CRMP4 antibodies help explore its potential as a biomarker or therapeutic target, particularly in conditions involving axonal degeneration or aberrant synaptic connectivity. Commercial CRMP4 antibodies are typically validated for specificity across human, mouse, and rat models, enabling cross-species translational research.